Catalyst Biosciences Announces Positive Factor IX Clinical Data
-- CB 2679d/ISU304 is approximately 22 times more potent than current hemophilia B therapy --
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced positive clinical data from the first Cohort of its ongoing Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B.
Cohort 1 results (N = 3) demonstrate:
An intravenous dose of CB 2679d is approximately 22 times more potent than an intravenous dose of BeneFIX® as measured by activity levels using a one-stage clotting assay; and
The average time that CB 2679d stayed in the circulation was significantly longer at 34 hours compared with BeneFIX at 25 hours.
Read more: Catalyst Biosciences Inc ( CBIO )
Published: 06 September 2017
Written by Editor